Clinical Trial Update: ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating whether genetically guided personalization of antiplatelet therapy improves outcomes in patients with stable coronary artery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Stable Coronary Artery Disease

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: Stable Coronary Artery Disease, Acute Coronary Syndrome | Phase 2, Phase 3 | Status: COMPLETED